Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Reynes

Showing results (91-100 of 200) with videos related to

Pageof 20
Sort By:
HIV Clinical Trials|March 18, 2015
The maraviroc expanded access program - safety and efficacy data from an open-label studyAdriano Lazzarin, Jacques Reynes, Jean-Michel Molina, et al.
AIDS Research and Human Retroviruses|June 27, 2012
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS studyJacques Reynes, Roger Trinh, Federico Pulido, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 15, 2012
Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT?Denis Mariano-Goulart, Jean-Marc Jacquet, Nicolas Molinari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Renal tubular dysfunction associated with tenofovir therapy: report of 7 casesHélène Peyrière, Jacques Reynes, Isabelle Rouanet, et al.
Antiviral Therapy|June 9, 2006
Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapyJean-Marie Bard, Régis Lassalle, Jacqueline Capeau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2003
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general populationMarianne Savès, Geneviève Chêne, Pierre Ducimetière, et al.
Clinical Pharmacology and Therapeutics|August 2, 2002
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment dispositionXiaoping Zhang, Keith Nieforth, Jean-Marie Lang, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 9, 2018
Osteomyelitis of the jaw: time to rethink the bone sampling strategy?Kevin Bertrand, Brigitte Lamy, Marie De Boutray, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2020
Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?Pierre Frange, Roland Tubiana, Jeanne Sibiude, et al.
AIDS (London, England)|April 13, 2004
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)Christine Katlama, Stéphanie Dominguez, Karine Gourlain, et al.
Pageof 20

Showing results (91-100 of 200) with videos related to

Sort By:
Pageof 20
HIV Clinical Trials|March 18, 2015
The maraviroc expanded access program - safety and efficacy data from an open-label studyAdriano Lazzarin, Jacques Reynes, Jean-Michel Molina, et al.
AIDS Research and Human Retroviruses|June 27, 2012
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS studyJacques Reynes, Roger Trinh, Federico Pulido, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 15, 2012
Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT?Denis Mariano-Goulart, Jean-Marc Jacquet, Nicolas Molinari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Renal tubular dysfunction associated with tenofovir therapy: report of 7 casesHélène Peyrière, Jacques Reynes, Isabelle Rouanet, et al.
Antiviral Therapy|June 9, 2006
Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapyJean-Marie Bard, Régis Lassalle, Jacqueline Capeau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2003
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general populationMarianne Savès, Geneviève Chêne, Pierre Ducimetière, et al.
Clinical Pharmacology and Therapeutics|August 2, 2002
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment dispositionXiaoping Zhang, Keith Nieforth, Jean-Marie Lang, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 9, 2018
Osteomyelitis of the jaw: time to rethink the bone sampling strategy?Kevin Bertrand, Brigitte Lamy, Marie De Boutray, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2020
Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?Pierre Frange, Roland Tubiana, Jeanne Sibiude, et al.
AIDS (London, England)|April 13, 2004
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)Christine Katlama, Stéphanie Dominguez, Karine Gourlain, et al.
Pageof 20